Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw…
Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera but said the Big Pharma “feels this deal will be…
After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks…
The Novo Nordisk Foundation has committed up to 200 million Danish kroner ($31 million) to support a new, artificial-intelligence-enabled system to monitor infectious disease outbreaks and bolster global pandemic preparedness.…